Skip to market wire
InvestLog
← Back to Stock Events← 返回个股快讯
REGNEarnings Release财报快讯Media source媒体来源Source link原始来源by InvestLog AIInvestLog AI 整理
Event time: 事件时间：
Published: 文章发布：

REGN earnings release — EPS beat +22.2% · revenue beat +12.1%再生元制药公司 (REGN) 财报发布 — EPS 高于预期+22.2% · 营收 高于预期+12.1%

Key Results

Actual vs Consensus

  • EPS: $20.07 vs $16.42 estimate, beat+22.2%.
  • Revenue: $5.1B vs $4.6B estimate, beat+12.1%.

    • Profitability and Cash Flow

  • Period: 2026 Q3 period ended 2026-09-30
  • Revenue: $5.1B; YoY: +36.3%; QoQ: +19.2%
  • Gross profit: $4.8B; Gross margin: 94.7%
  • Operating income: $2.0B; Operating margin: 40.0%; YoY: +99.5%; QoQ: +44.2%
  • Net income: $1.9B; GAAP diluted EPS: $18.45; YoY: +33.5%; QoQ: +50.3%
  • Cash: $0; Total debt: $2.0B; Net debt: $2.0B

    • Official release: Regeneron Reports Third Quarter 2026 Financial and Operating Results

    核心结果

    实际值与市场预期

  • EPS：$20.07 vs $16.42 预期，高于预期+22.2%。
  • 营收：$5.1B vs $4.6B 预期，高于预期+12.1%。

    • 财务指标

  • 期间：2026 Q3（截至 2026-09-30）
  • 营收：$5.1B；同比：+36.3%；环比：+19.2%
  • 毛利润：$4.8B；毛利率：94.7%
  • 经营利润：$2.0B；经营利润率：40.0%；同比：+99.5%；环比：+44.2%
  • 净利润：$1.9B；GAAP 稀释 EPS：$18.45；同比：+33.5%；环比：+50.3%
  • 现金：$0；总债务：$2.0B；净债务：$2.0B
    • View REGN stock details ->查看 REGN 个股详情 ->

    For information only. Not investment advice.内容仅供参考，不构成投资建议。

    Related articles相关阅读

    HSBC raises REGN target to $920 from $800HSBC 上调目标价 再生元制药公司 (REGN)：$800 → $920

    Rating Change · September 10, 2026评级变动 · 2026/9/10

    REGN earnings call: guidance, margins, analyst Q&ARegeneron Pharmaceuticals, Inc. (REGN) 电话会要点：指引、利润率、分析师问答

    Earnings Analysis · August 5, 2026财报电话会 · 2026/8/5

    REGN earnings release — EPS beat +40.6% · revenue beat +12.4%Regeneron Pharmaceuticals, Inc. (REGN) 财报发布 — EPS 高于预期+40.6% · 营收 高于预期+12.4%

    Earnings Release · August 5, 2026财报快讯 · 2026/8/5